BS01 in Patients With Retinitis Pigmentosa

• Status: Recruiting
• Trial end date: 2027-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bionic Sight LLC

Criteria

Inclusion Criteria:

• Confirmed diagnosis of retinitis pigmentosa

• Bare light perception in at least one eye

Exclusion Criteria:

• Prior receipt of any AAV gene therapy product

• Large amplitude nystagmus